메뉴 건너뛰기




Volumn 3, Issue 7, 2013, Pages 719-721

ERK pathway inhibitors: How low should we go?

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SCH 772984; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

EID: 84880299680     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0245     Document Type: Article
Times cited : (44)

References (12)
  • 2
    • 77957089182 scopus 로고    scopus 로고
    • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    • Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010; 107: 14903-8.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 14903-14908
    • Joseph, E.W.1    Pratilas, C.A.2    Poulikakos, P.I.3    Tadi, M.4    Wang, W.5    Taylor, B.S.6
  • 3
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF
    • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 2010; 464: 427-30.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 4
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
    • (2011) Nature , vol.480 , pp. 387-390
    • Poulikakos, P.I.1    Persaud, Y.2    Janakiraman, M.3    Kong, X.4    Ng, C.5    Moriceau, G.6
  • 6
    • 80051625929 scopus 로고    scopus 로고
    • Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    • Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
    • (2011) J Clin Oncol , vol.29 , pp. 3085-3096
    • Wagle, N.1    Emery, C.2    Berger, M.F.3    Davis, M.J.4    Sawyer, A.5    Pochanard, P.6
  • 7
    • 84856217925 scopus 로고    scopus 로고
    • Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
    • Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012; 31: 446-57.
    • (2012) Oncogene , vol.31 , pp. 446-457
    • Xing, F.1    Persaud, Y.2    Pratilas, C.A.3    Taylor, B.S.4    Janakiraman, M.5    She, Q.B.6
  • 8
    • 84869067183 scopus 로고    scopus 로고
    • Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
    • Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012; 22: 668-82.
    • (2012) Cancer Cell , vol.22 , pp. 668-682
    • Lito, P.1    Pratilas, C.A.2    Joseph, E.W.3    Tadi, M.4    Halilovic, E.5    Zubrowski, M.6
  • 9
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3    Coffee, E.M.4    Nishino, M.5    Cogdill, A.P.6
  • 11
    • 84880254869 scopus 로고    scopus 로고
    • Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
    • Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50.
    • (2013) Cancer Discov , vol.3 , pp. 742-750
    • Morris, E.J.1    Jha, S.2    Restaino, C.R.3    Dayananth, P.4    Zhu, H.5    Cooper, A.6
  • 12
    • 84873728334 scopus 로고    scopus 로고
    • Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    • Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-5.
    • (2013) Nature , vol.494 , pp. 251-255
    • Das Thakur, M.1    Salangsang, F.2    Landman, A.S.3    Sellers, W.R.4    Pryer, N.K.5    Levesque, M.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.